Carbon monoxide as a biomarker and therapeutic agent

A method of treating bronchitis secondary to or resulting in oxidative stress to a patient, comprising:

• identifying a patient suffering from bronchitis secondary to or resulting in oxidative stress;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the patient inhales the gaseous composition.

A method of treating cystic fibrosis secondary to or resulting in oxidative stress to a patient, comprising:

• identifying a patient suffering from cystic fibrosis secondary to or resulting in oxidative stress;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the patient inhales the gaseous composition.

A method of treating pneumonia secondary to or resulting in oxidative stress to a patient, comprising:

• identifying a patient suffering from pneumonia secondary to or resulting in oxidative stress;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the patient inhales the gaseous composition.

A method of treating interstitial lung disease secondary to or resulting in oxidative stress to a patient, comprising:

• identifying a patient suffering from interstitial lung disease secondary to or resulting in oxidative stress;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the patient inhales the gaseous composition.

A method of treating adult respiratory distress syndrome secondary to or resulting in oxidative stress to a patient, comprising:

• identifying a patient suffering from adult respiratory distress syndrome secondary to or resulting in oxidative stress;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 rpm to about 3000 ppm, wherein the patient inhales the gaseous composition.

A method of treating asthma in a human patient, comprising:

• identifying a human patient suffering from asthma;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the patient inhales the gaseous composition.

A method of treating asthma in a patient, comprising:

• identifying a patient suffering from asthma;
• and
• administering to the patient a therapeutically effective amount of a composition comprising carbon monoxide, wherein the composition contains 0.005% to 0.05% carbon monoxide, wherein the composition is administered as an inhaled gas.

A method of reducing inflammation secondary to sepsis in a patient, comprising:

• identifying a patient suffering from or at risk of sepsis;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby reduce inflammation secondary to sepsis, wherein the patient inhales the gaseous composition.

A method for reducing inflammation associated with a wound, the method comprising:

• identifying a patient suffering from a wound;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the amount is sufficient to reduce inflammation associated with the wound, wherein the patient inhales the gaseous composition.

A method of treating sepsis in a patient, comprising:

• identifying a patient suffering from or at risk of sepsis;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby treat sepsis in the patient wherein the patient inhales the gaseous composition.

A method of treating inflammation associated with arthritis in a patient, comprising:

• identifying a patient suffering from or at risk for arthritis;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby treat inflammation associated with arthritis in the patient, wherein the patient inhales the gaseous composition.

A method of treating a patient to reduce oxidative stress associated with hyperoxia, comprising:

• identifying a human patient suffering from or at risk for oxidative stress associated with hyperoxia;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby reduce oxidative stress associated with hyperoxia, wherein the patient inhales the gaseous composition.

A method of treating a patient to reduce hyperoxic lung injury, comprising:

• identifying a human patient suffering from or at risk for hyperoxic lung injury;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby reduce hyperoxic lung injury, wherein the patient inhales the gaseous composition.

A method of treating inflammation associated with Alzheimer's disease or Parkinson's disease, comprising:

• identifying a patient suffering from or at risk for Alzheimer's disease or Parkinson's disease;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby treat inflammation associated with Alzheimer's disease or Parkinson's disease, wherein the patient inhales the gaseous composition.

A method of treating inflammation in a patient, comprising:

• identifying a patient suffering from inflammation of at least one organ selected from the group consisting of brain, spleen, and skin;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, wherein the inflammation is of a type selected from the group consisting of acute, allergic, alternative, atrophic, catarrhal, croupous, fibrinopurulent, fibrinous, immune, hyperplastic, proliferative, subacute, serous and serofibrinous inflammation, wherein the patient inhales the gaseous composition.

A method of treating inflammation in a human patient, comprising:

• identifying a patient suffering from inflammation of at least one organ selected from the group consisting of brain, spleen, and skin;
• and
• administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 3000 ppm, to thereby treat inflammation in the human patient, wherein the patient inhales the gaseous composition.